Personalizing carbamazepine therapy
The anticonvulsant carbamazepine has a high incidence of cutaneous adverse drug reactions. A recent prospective clinical trial in Taiwan has indicated that HLA-B*1502 screening will reduce the incidence of life-threatening adverse reactions to carbamazepine, while a genome-wide association study has...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
BioMed Central
2011
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219069/ |